Although the determination of irisin is currently of no clinical relevance in terms of managing hypopituitary patients, in the near future it could be clinically applicable, as it has the potential to be a marker of physical exercise, sarcopenia or adiposity in different clinical situations, including hypopituitarism. This evidence concerns the gene FNDC5 and hypopituitarism.